Photobiomodulation for Diabetic Peripheral Neuropathy
NCT: NCT07613489 · ACTIVE_NOT_RECRUITING
Brief Summary
Diabetic peripheral neuropathy (DPN) is a common complication of long-term diabetes, affecting approximately 50 percent of patients. It causes tingling, numbness, and burning pain primarily in the feet, which reduces quality of life. Photobiomodulation therapy (PBMT), also known as low-level laser therapy, is a non-invasive treatment that may improve nerve function by reducing inflammation and promoting cellular repair. This randomized controlled trial aims to evaluate the effectiveness of PBMT in improving nerve function and quality of life in patients with DPN. A total of 36 participants with type 2 diabetes and DPN will be randomly assigned to either a treatment group receiving PBMT (900 nm wavelength, 25W, 1000 Hz frequency) or a control group receiving sham laser therapy. The intervention will be applied to the dorsum and plantar surface of the foot every other day for two weeks. Outcomes include pain intensity measured by the Numeric Pain Rating Scale and quality of life measured by the SF-36 questionnaire, assessed at baseline and after the intervention period.
Frequently Asked Questions
What is Photobiomodulation for Diabetic Peripheral Neuropathy?
Photobiomodulation for Diabetic Peripheral Neuropathy is a clinical trial registered under NCT07613489. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT07613489?
The current status of NCT07613489 (Photobiomodulation for Diabetic Peripheral Neuropathy) is: ACTIVE_NOT_RECRUITING.
When did Photobiomodulation for Diabetic Peripheral Neuropathy start?
Photobiomodulation for Diabetic Peripheral Neuropathy started on 2026-02-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.